Abstract
Ifosfamide is an alkylating agent used in the treatment of a variety of solid tumours. Ten to 15% of patients treated with ifosfamide develop an encephalopathy. Methylene blue (MB) may be used in the treatment of this encephalopathy. The purpose of this study was to evaluate the neuroprotective effect of MB in these patients and to review the literature. Between 1993 and 1997, 52 patients (age 16–77 years) with solid tumours were treated with ifosfamide in dosages ranging from 3 to 5 g m–2 q3w when given in combination schedules and up to 12 g m–2 q4w when given as a single agent. Twelve patients developed central nervous system (CNS) depression, defined as National Cancer Institute Common Toxicity Criteria (NCI-CTC) neurocortical toxicity grade 2 or higher. Eight were treated with MB at a dose of 6 × 50 mg day–1 intravenously (i.v.). Four recovered fully within 24 h, two recovered partially after 24 h and completely after 48 h while two recovered only after 72 h. Four patients did not receive MB and all recovered only after 48 h. Three patients received prophylaxis with MB at a dose of 4 × 50 mg day–1 i.v. for the subsequent chemotherapy cycles. Two developed milder encephalopathy; one had no CNS depression at all. We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy. Our findings suggest that it may also be used as a prophylactic agent. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aeschlimann C, Cerny T and Küpfer A (1996) Inhibition of (mono) amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Disp 24: 1336–1339
Aeschlimann C, Küpfer A, Schefer H and Cerny T (1998) Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Disp 26: 883–890
Alonso JL, Nieto Y, López JA, Martín M and Díaz-Rubio E (1996) Ifosfamide encephalopathy and methylene blue: a case report. Ann Oncol 7: 643–645
Cerny T, Castiglione M, Brunner K, Küpfer A, Martinelli G and Lind M (1990) Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 335: 175
Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB and Morrow P (1991) Ifosfamide-induced neurotoxicity. Gynecol Oncol 42: 193–196
Demandt M and Wandt H (1996) Erfolgreiche Behandlung von Ifosfamid-bedingten zentralnervösen Nebenwirkungen mit Methylenblau. Dtsch Med Wochenschr 121: 575
DiMaggio JR, Brown R, Baile WF and Schapira D (1994) Hallucinations and ifosfamide-induced neurotoxicity. Cancer 73: 1509–1514
Ferrero JM, Eftekari P, Largillier R, Dreyfus G and Namer M (1995) Traitement d’une encéphalopathie à l’ifosfamide par le bleu de méthylène. Bull Cancer 82: 598–599
Harpey JP, Charpentier C and Coudé M (1986) Methylene blue for riboflavin-unresponsive glutarica ciduria type II. Lancet I: 391
Hrushesky WJ, Olshefski R, Wood P, Meshnick S and Eaton JW (1985) Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet I: 565–567
Kaijser GP, Beijnen JH, Bult A and Underberg WJM (1994) Ifosfamide metabolism and pharmacokinetics. Anticancer Research 14: 517–532
Koschuth A, Späth-Schwalbe E and Possinger K (1996) Methylenblau bei Ifosfamid-induzierter Enzephalopathie. Dtsch Med Wochenschr 121: 1210
Küpfer A, Aeschlimann C, Wermuth B and Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 343: 763–764
Küpfer A, Aeschlimann C and Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50: 249–252
Kurowski V, Cerny T, Küpfer A and Wagner T (1991) Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117: S148–S153
Merimsky O, Reider-Groswasser I, Wigler N and Chaitchik S (1992) Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 86: 521–525
Pratt OE, Rooprai HK, Shaw GK and Thomson AD (1990) The genesis of alcoholic brain tissue injury. Alcohol Alcohol 25: 217–230
Van Tongelen K and Hawthorn J (1994). A Practical Guide to EORTC Studies. EORTC: Brussels
Watkin SW, Husband DJ, Green JA and Warenius HM (1989) Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 25: 1303–1310
Zulian GB, Tullen E and Maton B (1995) Methylene blue for ifosfamide associated encephalopathy. N Engl J Med 332: 1239–1240
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pelgrims, J., De Vos, F., Van den Brande, J. et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82, 291–294 (2000). https://doi.org/10.1054/bjoc.1999.0917
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0917
Keywords
This article is cited by
-
A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature
BMC Pediatrics (2022)
-
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile
Supportive Care in Cancer (2022)
-
Methylene blue can act as an antidote to pesticide poisoning of bumble bee mitochondria
Scientific Reports (2021)
-
Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report
Clinical Sarcoma Research (2020)
-
Selective Adsorption Capacity of Grape Marc Hydrogel for Adsorption of Binary Mixtures of Dyes
Water, Air, & Soil Pollution (2020)